Anemia in CKD: Find the Contributors Before Treating

Several mechanisms can coexist

Reduced erythropoietin activity, iron restriction, inflammation, blood loss, and shortened red cell survival contribute to CKD anemia. Kidney disease does not exclude nutritional deficiency, hemolysis, marrow disease, or gastrointestinal bleeding.

Recognize clinical impact

Fatigue, exertional intolerance, dyspnea, and reduced rehabilitation capacity may accompany anemia. Rapid decline, hemodynamic instability, ischemic symptoms, or suspected bleeding require urgent assessment beyond a routine chronic anemia pathway.

Build a diagnostic profile

Review hemoglobin trends, red cell indices, reticulocyte response, iron studies, and relevant nutritional tests. Interpret ferritin in the setting of inflammation and consider ongoing blood loss or other causes when the pattern is atypical.

Correct reversible factors

Treat iron deficiency and identified causes using an individualized oral or intravenous strategy. Decisions about erythropoiesis-stimulating treatment depend on symptoms, hemoglobin trajectory, dialysis status, risks, and informed preferences.

Apply the concept: Mercy anemia

The anemia exercise asks learners to connect laboratory findings with an appropriate treatment sequence. Confirm the likely mechanism, address iron availability, and establish a monitoring plan before escalating to erythropoiesis-stimulating therapy.

Use published 2026 guidance

The published KDIGO 2026 anemia guideline supports individualized treatment. Higher hemoglobin targets with erythropoiesis-stimulating therapy can add cardiovascular or thrombotic risk. Transfusion decisions also consider symptoms, alternatives, and transplant plans rather than one universal threshold.

Self-check: Before labeling anemia as renal, name the reversible causes and laboratory findings you would evaluate, then describe the risk of indiscriminate hemoglobin normalization.